Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Esophagus
Published in: Esophagus 4/2020

01-10-2020 | Esophageal Cancer | Editorial

Will definitive chemoradiotherapy be a new normal for patients with resectable locally advanced esophageal cancer?

Author: Hiroya Takeuchi

Published in: Esophagus | Issue 4/2020

Login to get access

Excerpt

Nowadays, neoadjuvant chemotherapy or chemoradiotherapy (CRT) followed by esophagectomy is the standard of care for patients with resectable locally advanced esophageal cancer worldwide [1‐3]. On the other hand, for patients unwilling to undergo esophagectomy, definitive CRT has been an alternative treatment for those with advanced esophageal cancer [4]. However, there are several problems to be resolved for conventional definitive CRT, such as a high incidence of late toxicities and poor survival. …
Literature
1.
Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92.CrossRef
2.
Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.CrossRef
3.
Van Hagen P, Hulchof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRef
4.
Hironaka S, Ohtsu A, Boku N, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2–3) N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2003;57:425–33.CrossRef
5.
Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94–05) Phase III trial of combined modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167–74.CrossRef
6.
Metadata
Title
Will definitive chemoradiotherapy be a new normal for patients with resectable locally advanced esophageal cancer?
Author
Hiroya Takeuchi
Publication date
01-10-2020
Publisher
Springer Singapore
Published in
Esophagus / Issue 4/2020
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-020-00780-3

Other articles of this Issue 4/2020

Esophagus 4/2020 Go to the issue

Original Article

The perioperative presepsin as an accurate diagnostic marker of postoperative infectious complications after esophagectomy: a prospective cohort study

Original Article

Circumferential Heller myotomy can relieve chest pain in patients with achalasia: a prospective clinical trial

Original Article

The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909

Original Article

High TLR4 expression predicts a poor prognosis after esophagectomy for advanced thoracic esophageal squamous cell carcinoma

Original Article

Clinical and endoscopic characteristics of diffuse esophageal intramural pseudo-diverticulosis

Original Article

Peroral endoscopic myotomy is a safe and effective treatment modality for geriatric patients with achalasia

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits